Pharmabiz

Amgen makes Repatha available through AmgenNow, a direct-to-patient programme in the US

Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...
Pharm Exec

Amgen Launches New Direct-To-Patient Program AmgenNow

AmgenNow, a direct-to-patient program, launches with Repatha, following positive Phase III Vesalius-CV trial results showing reduced cardiovascular events. Starting October 6, 2025, AmgenNow will be ...
Reuters

Amgen to sell cholesterol drug at 60% discount to cash-paying US patients

LOS ANGELES, Oct 6 (Reuters) - Amgen (AMGN.O), opens new tab on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the ...
Seeking Alpha

Amgen to offer Repatha at 60% discount to U.S. consumers

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...
Wall Street Journal

Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts

Amgen AMGN-0.60%decrease; red down pointing triangle slashed the price of its cholesterol medication by more than half for U.S. patients through a new medication-access program amid the Trump ...
Healio

Repatha made available via direct-to-patient program at discounted price

Please provide your email address to receive an email when new articles are posted on . Evolocumab will be made available to eligible patients via a new direct-to-consumer program. The PCSK9 inhibitor ...
Yahoo Finance

GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings

SANTA MONICA, Calif., October 06, 2025--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a ...
Becker's Hospital Review

Amgen launches direct-to-patient program to sell cholesterol drug at 60% discount

Amgen launched a direct-to-patient program Oct. 6 to offer its cholesterol medication Repatha at a reduced price. The AmgenNow program will provide Repatha for $239 per month — nearly 60% below the ...
Seeking Alpha

Amgen posts Phase 3 trial win for Repatha in major cardiovascular events

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a Phase 3 trial designed to evaluate its effect in reducing major adverse ...
Investing

Amgen’s Repatha reduces cardiovascular events in primary prevention study

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent player in the biotechnology industry with a market capitalization of $160.7 billion, announced Thursday that its Phase 3 VESALIUS-CV clinical ...
Morningstar

Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...